Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Columnist Jen Cueva has gotten more adept at listening to her body and making adjustments to manage her PH and leave room for joy.

Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...

Pulmonary hypertension (PH) risk grows over time for patients with narrowing of the aorta, the body's biggest blood vessel, ...